Table 1.
Characteristics | DR Positive N1 = 54 | DR Negative N2 = 34 | Total 88 | χ2 | P |
---|---|---|---|---|---|
No.(%) | No.(%) | No. | |||
Gender | 0.155 | 0.812 | |||
Male | 33 (61.1) | 23 (67.6) | 56 | ||
Female | 21 (38.9) | 11 (32.4) | 32 | ||
Age (years) | 5.133a | 0.162 | |||
6–20 | 5 (9.3) | – | 5 | ||
21–40 | 36 (66.7) | 26 (76.5) | 62 | ||
41–60 | 13 (24.0) | 7 (20.6) | 20 | ||
61–63 | – | 1 (2.9) | 1 | ||
Marital status | 0.329 | 0.828 | |||
Unmarried | 14 (25.9) | 7 (20.6) | 21 | ||
Married | 25 (46.3) | 17 (50.0) | 42 | ||
Divorced or widowed | 15 (27.8) | 10 (29.4) | 25 | ||
Route of transmission | 7.550a | 0.11 | |||
Blood-born (BB) | 2 (3.7) | – | 2 | ||
Injection Drug user (IDU) | 24(44.4) | 16 (47.1) | 40 | ||
Heterosexual (HST) | 20(37.0) | 18 (52.9) | 38 | ||
Mother to Children (MTC) | 3(5.6) | – | 3 | ||
Unknown | 5(9.3) | – | 5 | ||
Baseline CD4+ count (cells/μl) | 17.682a | 0.001 | |||
0–200 | 27(50.0) | 8 (23.5) | 35 | ||
201–350 | 21(38.9) | 21 (61.8) | 42 | ||
351–500 | – | 5 (14.7) | 5 | ||
undetected | 6(11.1) | – | 6 | ||
Area | 9.069a | 0.526 | |||
Kunming | 13(24.1) | 9(26.5) | 22 | ||
Lincang | 8(14.8) | 6(17.6) | 14 | ||
Honghe | 8(14.8) | 4(11.8) | 12 | ||
Chuxiong | 3(5.6) | 6(17.6) | 9 | ||
Nujiang | 3(5.6) | – | 3 | ||
Puer | 2(3.7) | 2(5.9) | 4 | ||
Zhaotong | 6(11.1) | 3(8.8) | 9 | ||
Dali | 3(5.6) | 3(8.8) | 6 | ||
Baoshan | 2(3.7) | – | 2 | ||
Wenshan | 4(7.4) | 1(2.9) | 5 | ||
Yuxi | 2(3.7) | – | 2 | ||
Therapeutic regimen | 11.809a | 0.107 | |||
3TC + NVP + AZT | 19(35.2) | 21(61.8) | 40 | ||
3TC + NVP + D4T | 16(29.6) | 5(14.7) | 21 | ||
EFV + 3TC + AZT | 12(22.2) | 5(14.7) | 17 | ||
EFV + 3TC + D4T | 1(1.9) | 3(8.8) | 4 | ||
EFV + 3TC + TDF | 3(5.6) | – | 3 | ||
3TC + AZT + Lpv/r | 1(1.9) | – | 1 | ||
NVP + DDI + D4T | 1(1.9) | – | 1 | ||
Lpv/r + 3TC + ABC | 1(1.9) | – | 1 |
aFisher’s exact probability Chisquare test. 3TC:Lamivudine, NVP:Nevirapine, D4T:Stavudine, AZT:Zidovudine, EFV:Efavirenz, TDF:Tenofovir disoproxil fumarate Lpv/r:Lopinavir/Ritonavir